Gestational trophoblastic neoplasia (GTN) can result from the over-proliferation of trophoblasts. Treatment of choriocarcinoma, the most aggressive GTN, currently requires high doses of systemic chemotherapeutic agents, which result in indiscriminate drug distribution and severe toxicity. To overcome these disadvantages and enhance the chemotherapeutic efficacy, chondroitin sulfate A (CSA)-binding nanoparticles were developed for the targeted delivery of doxorubicin (DOX) to choriocarcinoma cells using a synthetic CSA-binding peptide (CSA-BP), derived from malarial protein, which specifically binds to the CSA exclusively expressed in the placental trophoblast. CSA-BP-conjugated nanoparticles rapidly bonded to choriocarcinoma (JEG3) cells and were efficiently internalized into the lysosomes. Moreover, CSA-BP modification significantly increased the anti-cancer activity of the DOX-loaded nanoparticles in vitro. Intravenous injections of CSA-BP-conjugated nanoparticles loaded with indocyanine green (CSAINPs) were rapidly localized to the tumor. The CSA-targeted nanoparticles loaded with DOX (CSA-DNPs) strongly inhibited primary tumor growth and, more importantly, significantly suppressed metastasis in vivo. Collectively, our results highlight the potential of the CSA-BP-decorated nanoparticles as an alternative targeted delivery system of chemotherapeutic agents for treating choriocarcinoma and for developing new GTN therapies based on drug targeting.
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Introduction
Gestational trophoblastic neoplasia (GTN) causes malignant lesions arising from the over-proliferation of placental trophoblasts and includes invasive moles, choriocarcinoma, placental site trophoblastic tumors, and epithelioid trophoblastic tumors (Lurain, 2011; Nadhan et al., 2017) . Gestational choriocarcinoma, the most aggressive gestational trophoblastic disease, develops in approximately one in every 50,000 pregnancies (Seckl et al., 2010) and triggers massive local trophoblast invasion and vascular permeation, leading to metastasis to the brain, kidney, liver, and lung (Shih, 2007; Cheung et al., 2009 ). The serum concentrations of human chorionic gonadotropin (hCG) increase in advanced stages of choriocarcinoma and are useful for diagnosing choriocarcinoma and for monitoring the effects of chemotherapy on the disease progression (Kohorn, 2001) . Depending on the Federation of Gynecology and Obstetrics (FIGO) score of choriocarcinoma, the first-line treatment is either single agent systemic chemotherapy or a polychemotherapy regimen of methotrexate, etoposide, actinomycin D, cyclophosphamide, and vincristine (Taşçı et al., 2016; Frost et al., 2017) . However, the systemic administration of chemotherapeutic agents results in indiscriminate drug distribution and severe toxicity. Nanomedicine is a multidisciplinary research field that merges concepts from medicine and nanotechnology with the overall goal of accurately fine-tuning the biological processes occurring at the micron and submicron scales (Ferrari, 2005; Peer et al., 2007; Riehemann et al., 2009) . One of the great advantages of nanomedicine over traditional molecular therapeutics is the ability to vector drugs preferentially to the affected loci, thus increasing drug efficacy and reducing associated adverse reactions. Our collaborative team has developed a lipid-polymer nanoparticle platform that has been adapted to simultaneously deliver high-dose chemotherapy and photothermal agents to tumor regions in a breast cancer xenograft mouse model without having adverse effects (Zheng et al., 2013; Zhao et al., 2014) .
Another important recent advance has been the clarification of the key event underlying placental malaria pathogenesis and the concurrent discovery of the malarial protein VAR2CSA. Specifically, the malaria parasite Plasmodium falciparum replicates within infected erythrocytes (IEs), which effectively sequester in the placental intervillous spaces of a pregnant woman. Placental adherence is mediated by the malarial VAR2CSA protein exposed on the IE membrane (Salanti et al., 2004; Gamain et al., 2005; Duffy et al., 2006) . This protein binds a distinct type of chondroitin sulfate A (CSA) that is exclusively expressed in placental syncytiotrophoblasts (Fried & Duffy, 1996; Salanti et al., 2003 Salanti et al., , 2004 Salanti et al., , 2015 . Notably, the minimal CS binding region of VAR2CSA consists of the Duffy binding ligand-like (DBL) 2X domain with flanking interdomain (ID) regions (Dahlb€ ack et al., 2011; Clausen et al., 2012) . Furthermore, the binding of this domain to CS was confirmed using a synthetic CSA-binding peptide (CSA-BP) (Resende et al., 2008) .
Inspired by the new insights into placental malaria, we hypothesized that the CSA-BP could be used as a tool for the targeted delivery of chemotherapeutic agent-loaded nanoparticles to placental trophoblasts to treat GTN, particularly choriocarcinoma. In the present study, we investigated the targeted choriocarcinoma efficacy of CSA-targeted nanoparticles in vitro, in vivo, and ex vivo. Moreover, the efficacy of the CSA-targeted nanoparticles loaded with doxorubicin (CSA-DNPs) in alleviating the primary tumor burden and inhibiting choriocarcinoma metastasis was studied by administering the CSA-DNPs to tumor-bearing mice following multiple intravenous injections.
Materials and methods
Chemicals
Soybean lecithin and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy (polyethylene glycol)-2000] (DSPE-PEG-COOH) were purchased from Avanti Polar Lipids (Alabaster, AL). Poly(DL-lactic-co-glycolic acid) (50:50) (PLGA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), doxorubicin (DOX) and indocyanine green (ICG) were purchased from Sigma-Aldrich (St. Louis, MO). CSA-binding peptide (EDVKDINFDTKEKFLAGCLIVSFHEGKC) (Resende et al., 2008) and the scrambled peptide (SCR, EVDNDKKLGLVFEKD KIFTEFACISHCG) were synthesized by ChinaPeptides Co., Ltd. (Shanghai, China) and Shanghai GL Biochem Co. Ltd. (Shanghai, China), respectively. Unless stated otherwise, all other materials used were obtained from Sigma-Aldrich (St. Louis, MO).
Cell lines and transfection
JEG3 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM/F12 (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY) . To produce the firefly luciferase (Fluc)-GFP-positive JEG3 cell line (Fluc-GFP-JEG3), lentiviruses expressing the Fluc and GFP fusion protein (LV-Fluc-GFP) were produced as described previously (Fan et al., 2011) and then were used to transduce the JEG3 cells. The LV-Fluc-GFP-transduced JEG3 cells were sorted for pure Fluc-GFP-positive JEG3 cells using BD FACSAria III (BD Biosciences, San Jose, CA).
Preparation of DNPs and INPs
DOX-loaded nanoparticles (DNPs) or ICG-loaded nanoparticles (INPs) were synthesized from PLGA, soybean lecithin, DOX or ICG, and DSPE-PEG-COOH using the single-step sonication method (Zheng et al., 2013) . PLGA was dissolved in acetonitrile with a concentration of 2 mg/mL. Stock solutions of soybean lecithin and DSPE-PEG-COOH were dissolved separately in 4% ethanol aqueous solutions with concentrations of 1 mg/mL, and DOX or ICG was prepared at a concentration of 10 mg/mL in ultrapure water. To prepare the DNPs, 750 lg of DOX, 90 lg of soybean lecithin and 210 lg of DSPE-PEG-COOH were added to 3 mL of a 4% ethanol aqueous solution, and then, 1 mL PLGA acetonitrile solution was added dropwise under sonication using an ultrasonic processor (VCX130, Newtown, CT) at a frequency of 20 kHz and a power of 130 W for 5 min. The DNPs were then concentrated by ultracentrifugation (34,000Âg) (Optima TM MAX-XP, Beckman, Brea, CA) at 4 C for 30 min. After discarding the supernatant, the samples were re-suspended in 1 mL of phosphate-buffered saline (PBS, pH7.4). Purification was performed by washing the DNPs in PBS three times using an Amicon ultra-4 centrifugal filter (MWCO 10 kDa, Millipore, Billerica, MA). The same procedure was used to prepare the INPs by replacing DOX with the same amount of ICG.
Conjugation of CSA-BP or the SCR to the nanoparticles
Peptides were conjugated to the nanoparticle surface using the EDC/NHS technique (Wen et al., 2017) . Briefly, to conjugate the DNPs with the CSA-BP or SCR, the carboxyl groups were activated by adding an activation buffer, EDC and NHS with a DSPE-PEG-COOH:NHS:EDC feed molar ratio of 1:2:2. The EDC/NHS solution was mixed vigorously with the DNPs at room temperature for 30 min, and then, CSA-BP or SCR was added with a feed molar ratio of peptide to DSPE-PEG-COOH of 2:1. The mixture was stirred at room temperature for 2 h and then stored at 4 C overnight. The products were concentrated again to remove un-conjugated peptides and purified as described above. The CSA-BP-and SCR-conjugated INPs were also prepared using the same method.
Characterization of the nanoparticles
The surface charge, size, polydispersity, and size distribution of the nanoparticles were determined by dynamic light scattering analysis using a Malvern Zetasizer (Nano ZS, Malvern, UK) at room temperature. The morphology and particle size of the nanoparticles were further analyzed using a transmission electron microscope (TEM, JEM-100CXII, JEOL, Tokyo, Japan) with the negative stain method. Briefly, the samples were soaked onto a copper grid for 5 min, and excess liquid was removed with filter paper. The grid was stained with 2% (w/v) phosphotungstic acid and dried at room temperature before image acquisition.
The encapsulation efficiency (EE) and loading efficiency (LE) of DOX in the nanoparticles were determined as follows: before ultrafiltration, the fresh nanoparticles were isolated from the aqueous suspension medium by ultracentrifugation (34,000Âg, 30 min) (Optima TM MAX-XP, Beckman, Brea, CA) at 4 C. The non-entrapped DOX in the supernatant was determined using a fluorescence spectrophotometer (F900, Edinburgh Instruments Ltd., Livingston, UK) with excitation at 480 nm and emission at 593 nm. The EE and LE were calculated as follows:
EE ¼ ((weight of loaded DOX)/(weight of total added drug)) Â 100%, and LE ¼ ((weight of loaded DOX)/(total weight of materials)) Â 100%.
A dialysis experiment was performed to analyze the DOX release from the different DOX formulations. PBS (pH 7.4) was used as the releasing medium. Different DOX formulations containing 60 lg of DOX were dispersed in 1 mL of PBS and added into the dialysis bags; then, the bags were incubated in 100 mL of PBS at 37 C under continuous shaking. At predetermined time points, the dialysate was removed to estimate the amount of drug released, while an equal volume of fresh PBS was added to replace the removed volume for further analysis. The DOX concentration in the samples was measured using the fluorescence spectrophotometer as described above.
The concentration of peptides in the supernatant was determined by high-performance liquid chromatography (HPLC, experimental details are in the supporting information). The peptides conjugation efficiency was calculated as follows:
conjugation efficiency ¼ ((total amount -amount in supernatant)/total amount) Â 100% (Zhang et al., 2013) .
Cellular uptake of CSA-targeted nanoparticles
The cellular uptake of the different nanoparticles was observed under a fluorescence microscope. First, JEG3 cells grown to 60% confluence in 12-well plates were incubated with free DOX, the DNPs, the SCR-DNPs, or the CSA-DNPs (5 lg of DOX equivalent) for 1 h at 4 C. Then, the cells were washed with PBS to remove the unbound DOX or nanoparticles and incubated for 30 min at 37 C to allow internalization of only the surface-bound nanoparticles. Then, the cells were washed three times with PBS, fixed with 4% paraformaldehyde for 15 min and stained with DAPI for 10 min at room temperature. Finally, the cells were visualized under a fluorescence microscope (OLYMPUS IX71, Tokyo, Japan).
For quantitative analysis, the DOX content of the supernatant was detected using a fluorescence spectrophotometer (F900, Edinburgh Instruments Ltd., Livingston, UK) with excitation at 480 nm and emission at 593 nm. Meanwhile, the JEG3 cells were harvested, suspended in 0.5 mL of PBS (0.01 M, pH7.4), and analyzed by flow cytometry (BD, San Jose, CA).
Subcellular colocalization
The subcellular location of the endocytosed drugs was analyzed using confocal microscopy. Briefly, JEG3 cells were seeded on coverslips and allowed to attach overnight. Then, the medium was replaced with fresh medium supplemented with the CSA-DNPs (containing 5 lg/mL of DOX), 100 nM of LysoTracker Green (Life Technologies, Carlsbad, CA) and 10 lg/mL of Hoechst 33258 (Invitrogen, Carlsbad, CA). The cells were incubated at 37 C for 30 min and then fixed with 4% paraformaldehyde. Finally, the subcellular localization of the drugs in the cells was observed using confocal laser scanning microscopy (TCS SP5, Leica, Hamburg, Germany).
In vitro cell viability study
Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) assay according to the manufacturer's instructions. Briefly, JEG3 cells were seeded into 96-well plates at a density of 5000 cells/well. Twentyfour hours later, the medium was replaced with fresh culture medium containing free DOX, the DNPs, the SCR-DNPs, or the CSA-DNPs at DOX concentrations ranging from 0.2 lg/mL to 2 lg/mL. After 24 h, 10 lL of the CCK-8 solution was added to each well, and the plate was incubated at 37 C for 1 h; then, the absorption at 450 nm was detected using a microplate reader (ThermoFisher, Waltham, MA). The IC 50 values were calculated as the concentration of drugs required to inhibit cell growth by 50% compared with the controls and were determined using GraphPad Prism 6.0 software (San Diego, CA).
Cell apoptosis assay
An Annexin V-FITC/propidium iodide (PI) Apoptosis Detection Kit (Beyotime Institute of Biotechnology, Haimen, China) was used to detect the apoptotic cells according to the manufacturer's instructions. Briefly, JEG3 cells were seeded in 60-mm dishes at a density of 1 Â 10 5 cell/mL. After 24 h, the cells were treated with or without different nanoparticles (DOX concentration of 0.4 lg/mL). After 24 h, the cells were harvested and resuspended in 0.5 mL of detection buffer containing 10 lL of PI and 5 lL of Annexin V-FITC. Cellular apoptosis was detected and analyzed using flow cytometry (FACSCalibur, BD, San Jose, CA).
Specific targeting of CSA-NPs in vivo
All animal procedures were approved and performed in accordance with the Guidance Suggestions for the Care and were injected intravenously in the tail vein of the mice. Then, the mice were imaged using an IVIS spectrum imaging system (excitation, 710 nm; emission, 840 nm; Perkin-Elmer, Waltham, MA) from 10 min to 48 h. Forty-eight hours after the nanoparticle injection, the mice were anesthetized with 30% urethane. Fluc-GFP-JEG3 tumors were then collected, and immunofluorescence analysis was performed according to the published procedures (Fan et al., 2014) . Briefly, tissues were fixed in 4% paraformaldehyde overnight. After dehydration in 30% sucrose, the tissues were embedded in OCT and frozen. The tumor tissue sections (10 lm) were then stained with DAPI for 10 min at room temperature. Finally, sections were visualized using confocal laser scanning microscopy (TCS SP5, Leica, Hamburg, Germany).
Tumor models and bioluminescent imaging
For the metastasis model, Fluc-GFP-JEG3 cells (10 6 cells/ mouse) were injected into the lateral tail vein of 4-to 6-week-old female nude mice (BALB/c background). Tumor metastases were evaluated by restricting the region of interest of the bioluminescent image to that of the originally occupied area. To establish the xenograft model, Fluc-GFP-JEG3 cells (10 6 cells/mouse) were implanted by subcutaneous injection into the right flank region of the mice. The mice were randomly allocated into one of five treatment groups: those treated with the CSA-DNPs, the DNPs, the SCR-DNPs, free DOX (10 mg/kg DOX equivalent per mouse), or PBS alone. Treatments were administered intravenously from day 2 after the xenograft implantation and imaged using the IVIS spectrum imaging system (Perkin-Elmer, Waltham, MA); this process was repeated every other day, with tumor volumes (calculated as (tumor length) Â (tumor width) 2 /2) measured and recorded until 18 days after the xenograft.
Statistical analysis
Statistical values were defined using unpaired Student's t-test, with a p value less than .05 considered statistically significant. All statistical analyses were performed using GraphPad Prism 6.0 software (San Diego, CA).
Results
Characterization of the CSA-DNPs
The synthetic procedure is detailed in Figure 1(A) . The DNPs were self-assembled from DOX, PLGA, lecithin, and DSPE-PEG-COOH through a single-step sonication method. Bioconjugation was performed between the amino-terminal fragment of the peptide and the carboxyl groups on the surface of the DNPs. The mean diameters and zeta potentials of the nanoparticles are shown in Table S1 and Figure 1(B) . The sizes of the DNPs, SCR-DNPs, and CSA-DNPs were 82.3 ± 4.7 nm, 99.6 ± 4. 2 nm, and 109.3 ± 5.9 nm, respectively, indicating that peptide conjugation significantly increased the size of the nanoparticles. Meanwhile, the TEM image of the CSA-DNPs also showed that the particles had generally spherical morphologies (Figure 1(D) ). In addition, the peptide used in the present study was not large enough to cause notable changes in the surface charge, thus reducing the influence of surface charge on the nanoparticle behavior in vitro and in vivo (Alexis et al., 2008) . The efficiency of conjugating the CSA-BP and SCR to the DNPs was 49.3 ± 4.4% and 56.7 ± 3.1%, respectively. The EE of DOX for DNPs, SCR-DNPs, and CSADNPs was 40.3 ± 1.67%, 38.8 ± 1.83%, and 39.5 ± 1.94%, respectively. The LE of DOX for DNPs, SCR-DNPs, and CSADNPs was 6.2 ± 0.74%, 5.3 ± 0.56%, and 5.1 ± 0.42%, respectively. These data indicated that the drug encapsulation ability and loading ability were maintained after peptide decoration.
The in vitro release profiles of the DNPs, SCR-DNPs, and CSA-DNPs displayed a similar biphasic pattern (Figure 1(C) ), which was characterized by a fast initial release within the first 24 h (approximately 50% release) and a slower and continuous release in the following 48 h (approximately 60% release). These results suggested that conjugating the peptide did not significantly influence the in vitro release pattern of DOX.
Cellular uptake and internalization of CSA-DNPs
To test whether conjugating the CSA-BP to the nanocarriers increases the nanoparticle uptake into tumors, JEG3 cells were incubated with the different nanoparticle formulations. Fluorescent microscopy and flow cytometry analysis showed that the nanoparticle uptake into cells was three-fold higher for the CSA-targeted formulation than that for the non-targeted control (Figure 2(A,B) ). This result was confirmed by the significantly less DOX that was found in the supernatant of CSA-targeted nanoparticles (Figure 2(C) ). In addition, conjugating the SCR did not result in an enhancement of nanoparticle uptake into JEG3 cells, showing the specific role of CSA in the tumor cell uptake of targeted nanoparticles.
The intracellular localization of nanomaterials has been reported to typically involve the lysosomes after the entry of the materials into cells (Zhao et al., 2011 (Zhao et al., , 2016 . We further investigated the intracellular localization of CSA-DNPs incubated with cells for 30 min at 37 C, and then, we removed Based on these data, we conclude that the CSA-targeted nanoparticles are rapidly bound to JEG3 cells and are efficiently internalized into the lysosomes.
CSA-DNPs display strong growth inhibition and apoptotic effects on JEG3 cells
Next, the CCK-8 assay was used to evaluate the viability of JEG3 cells after 24 h of treatment with the different nanoparticle formulations. The cell viability profiles of the JEG3 cells exhibited that both the targeted (CSA-DNPs) and non-targeted (DNPs and SCR-DNPs) nanoparticles exerted a dosedependent cytotoxic effect. At doses of 0.4-2 lg/mL, the CSA-DNPs displayed stronger killing effects on the JEG3 cells than the DNPs or SCR-DNPs (Figure 3(A) ). The doses for the cytotoxic effect were determined based on the IC 50 values of these nanoparticles. The IC 50 of the CSA-DNPs (0.4 lg/mL) in JEG3 cells was significantly lower than the DNPs (0.69 lg/mL), the SCR-DNPs (0.70 lg/mL), and free DOX (0.90 lg/mL). A quantitative apoptosis assay revealed that after treatment with the CSA-DNPs, the percentage of JEG3 cells in early apoptotic and late apoptosis stages was significantly increased and was 2.4-fold higher than that of free DOX; by contrast, for the cells treated with the DNPs and SCR-DNPs, the number of apoptotic cells was similar, and this value was 1.4-and 1.3-fold higher than that of free DOX, respectively (Figure 3(B) ). These data were in agreement with the cellular uptake results, demonstrating that conjugating the DNPs with the CSA-BP leads to strong growth inhibition and apoptosis in JEG3 cells.
In vivo localization of CSA-INPs
To investigate the tumor targeting of the CSA-NPs in vivo, nude mice bearing Fluc-GFP-JEG3 tumors in their right flank were injected intravenously with the CSA-INPs or INPs. Within the tumor region, the ICG signal from the CSA-INPs was rapidly observed after 10 min in vivo and could be followed for 48 h after injection. By contrast, there was no ICG signal in the tumor region of mice treated with the INPs (Figure  4(A,B) ). Moreover, ex vivo immunofluorescence analysis of fixed Fluc-GFP-JEG3 xenografts strongly confirmed the ability of the CSA-INPs to target tumors (Figure 4(C) ). These data suggest that the CSA-modified nanoparticles can rapidly target tumors and can be utilized to delivery cytotoxic compounds to tumors in vivo.
CSA-DNPs effectively inhibit primary human choriocarcinoma growth in mice
To evaluate the in vivo effect of our CSA-targeted DNPs, Fluc-GFP-JEG3 cells were grafted into the right flank regions of nude mice. Starting at day 2, the mice were treated with the CSA-DNPs, DNPs, SCR-DNPs, free DOX (10 mg/kg DOX equivalent), or PBS alone every other day. The primary tumor burden was monitored using bioluminescent imaging and caliper measurements. Compared with the other groups, the group of mice treated with the CSA-DNPs exhibited a significantly reduced primary tumor burden and no macroscopic tumor growth, whereas the non-targeted SCR-DNPs did not enhance the antitumor effects of DOX ( Figure 5(A-C) ). Remarkably, the luciferase activity in the Fluc-GFP-JEG3 cells could not be detected in two of the five mice in the CSA-DNP-treated group 18 days after treatment ( Figure 5(A) ). In addition, all the mice in the PBS group were dead 18 days after tumor implantation (median survival, 14 days). At day 18, a significant increase in survival (100%) was observed in the CSA-DNP-treated mice compared with the mice in the DNPs, SCR-DNPs (40%) and free DOX (20%) groups. All the mice in the CSA-DNP treatment group were alive after the 30-day survival studies (Figure 5(D) ). Throughout the entire course of treatment, no significant difference in body weights was observed across the different treatment groups, demonstrating the low toxicity of the targeted CSA-DNPs and nontargeted DNPs or SCR-DNPs administered via intravenous injections ( Figure 5(E) ). Collectively, these data highlight the effectiveness and safety of the systemic administration of the CSA-DNPs for the inhibition of primary human choriocarcinoma growth in mice. 
CSA-DNPs inhibit human choriocarcinoma metastasis in mice
We further tested the efficacy of CSA-DNPs in a human choriocarcinoma metastasis mouse model. At day 10 after the Fluc-GFP-JEG3 cells were implanted, mice autopsies and bioluminescent imaging revealed abundant metastatic foci in the lung, liver, kidney, uterus, ovary, and brain of the mice (Figure 6(B) ). These data corresponded to the previously reported (Shih, 2007; Cheung et al., 2009 ) theory that the metastasis of choriocarcinoma occurs via a hematogenous route to many distant organs. Starting on day 2, the animals received intravenous injections of the CSA-DNPs, DNPs, SCRDNPs, or free DOX (10 mg/kg DOX equivalent) every other day. Compared with the control groups, CSA-DNP treatment resulted in robust inhibition of tumor metastasis ( Figure  6(A,C) ). Interestingly, treatment with the DNPs or SCR-DNPs also slightly inhibited tumor metastasis compared with treatment with free DOX. This result demonstrated that the nanoparticles could reach tumors via the enhanced permeability and retention (EPR) effect (Chisholm et al., 2009; Manzoor et al., 2012; Guo & Huang, 2014) . However, these nanoparticles lacked a specific targeting and binding action to the choriocarcinoma cells, so the efficiency of the anti-cancer effect was lower than when using the targeted CSA-DNPs. Taken together, these results show that the CSA-DNPs could effectively inhibit human choriocarcinoma progression and metastasis.
Discussion
GTN was the first cancer that exhibited high cure rates when treated with chemotherapy; these cure rates could exceed 98% with fertility retention, which is relatively high compared to other types of cancers (Seckl et al., 2010; Lim et al., 2017) . However, GTN still requires high-dose systemic chemo-drug delivery (Seckl et al., 2013) , which is harmful to healthy tissues and organs. In this report, we demonstrate the feasibility of using a CSA-BP conjugated to nanoparticles loaded with DOX (CSA-DNPs) to enhance nanoparticle uptake, resulting in the inhibition of cell viability and an increase in the apoptosis of choriocarcinoma in JEG3 cells in vitro. Moreover, we demonstrated that CSA-BP-modified INPs rapidly localized to the tumor after being intravenously injected in vivo and that the CSA-DNPs efficiently killed tumor cells and strongly inhibited JEG3 cell metastasis in tumor-bearing mice following multiple intravenous injections. Overall, our results indicate that these nanoparticles can be used as an alternate targeting method for choriocarcinoma treatment and as a support for the development of new drug targeting methods for GTN therapies.
Lipid-polymer nanoparticles present a new and promising drug delivery platform with the unique advantages of both liposomes and polymeric nanoparticles, including controllable particle size and surface functionality. These nanoparticles have demonstrated a high drug-loading yield, a sustained drug release profile, and excellent in vitro and in vivo stability (Zhang et al., 2008; Fang et al., 2010; Zheng et al., 2013) . In this study, to generate the lipid-polymer nanoparticles, a single-step sonication method was used to induce self-assembly of the lipids and polymers. Free PLGA (polymers) is dissolved in acetonitrile (water-miscible organic solvent), while lecithin (lipid) and DSPE-PEG-COOH (lipid-PEG conjugates) are dispersed in a 4% ethanol aqueous solution. The PLGA solution is then added to the lecithin aqueous solution dropwise under sonication. When the organic solvent diffuses into the aqueous solution, the PLGA precipitates into small nanoparticles. The lecithin and DSPE-PEG-COOH spontaneously selfassemble on the surface of these PLGA nanoparticles through hydrophobic interactions to reduce the system's free energy. The hydrophobic tail of lecithin adheres to the hydrophobic PLGA core, and the hydrophilic headgroup of lecithin extends into the external aqueous environment. The DSPE-PEG-COOH participates in the self-assembly process with the DSPE moiety being inserted into the lecithin monolayer and with -PEG-COOH facing outward from the lecithin monolayer to form lipid-polymer nanoparticles.
The drug loading and EE of nanoparticles are crucial for a successful drug delivery system. Increasing the drug content of the nanoparticles with an increased theoretical drug loading may have resulted in increasing the particle size (Dong & Feng, 2004) . The particle size plays an important role in determining the drug release behavior of nanocarriers as well as their fate after administration. It has been reported that nanoparticles between 100 and 200 nm have a favorable EPR effect within tumor vasculature (Guo et al., 2011) . Moreover, an increase in the drug loading might increase the nanoparticle polydispersity. If the drug concentration is increased to a threshold of the solubilization capacity of the particles, then notable precipitation will occur (Liu et al., 2006) . It was reported that the particles were more stable when the drug loading levels were lower (Lin et al., 2003) . Meanwhile, the drug loading amount is the key factor for the drug EE. Previous studies showed that a higher drug load resulted in a lower drug EE (Govender et al., 1999; Dong & Feng, 2004) . Therefore, in the nanoparticle delivery system, the compatibility between the drug and the particle size is of utmost importance. In the present work, drug loadings of approximately 5% were found to minimize the nanoparticle size and polydispersity, and at this drug loading amount, the fabricated nanoparticles may be more stable and behave more predictably in vivo.
Recently, Salanti et al. demonstrated that CSA is exclusively expressed on trophoblastic cells and in most human tumors. They also showed that using the malarial protein VAR2CSA enabled the targeted delivery of anti-cancer compounds into the tumor (Salanti et al., 2015; Seiler et al., 2017). In the present study, a novel trophoblast-targeted nanoparticle system is described for delivering DOX into choriocarcinoma cells using a synthetic CSA-BP derived from VAR2CSA. We showed that the CSA-DNPs could specifically bind to JEG3 choriocarcinoma cells both in vitro and in vivo. Additionally, the CSA-DNPs were rapidly internalized in 30 min via endocytosis and accumulated in the lysosomes where the acidic lysosome environment and enzyme catalysis facilitated the rapid degradation of the nanoparticles and released the loaded DOX into the cytoplasm. Then, DOX traveled to the nucleus (Cui et al., 2017) and induced JEG3 cell apoptosis. Moreover, the systemic administration of the CSADNPs led to an enhanced killing of the primary tumor and inhibition of metastasis. Notably, the delivery of DOX to the tumors in vivo using these CSA-targeted nanoparticles minimizes potential toxic side effects. Overall, this improvement resulted in a substantial enhancement of animal survival compared to the control groups. In summary, in line with previous studies (Salanti et al., 2015; Seiler et al., 2017) , our data highlight CSA as a marker for a human tumor therapy strategy, and the results indicate that the CSA-BP may be a novel tool for the targeted delivery of drugs to most human cancer cells.
Despite being a recombinant malarial protein, VAR2CSA has been used for the delivery of anti-cancer compounds directly to human tumor cells (Salanti et al., 2015) . However, when VAR2CSA is conjugated with nanoparticles, the high molecular weight of the full-length protein may limit its penetration into tumor tissues, and the specificity of the tumor-targeted nanoparticles may be affected by the interaction of the whole protein with normal tissues. The high cost of VAR2CSA also limits its wide use as a ligand for tumor-targeted nanoparticles. Using a synthetic CSA-BP overcomes these problems and has many advantages, such as low molecular weight, small size and low immunogenicity. Importantly, human tumor tissue microarray analysis demonstrated that the CSA-BP could broadly target human cancer cells, including those of hematopoietic, epithelial and mesenchymal origin (unpublished data). Although the partial peptide binding affinity may be lower than that of the intact protein (Resende et al., 2008) , CSA-BP conjugated to the nanoparticle surface can form a multivalent bond with receptors because of the multiple copies of CSA-BP on the nanoparticle surface, which in principle, enables increased functional affinity. Thus, the CSA-BP is particularly suitable for the engineering of targeted nanoparticles.
Conclusions
In summary, the successful application of CSA-BP-modified nanoparticles was demonstrated as an efficient tool for the targeted delivery of chemotherapeutic agents to choriocarcinoma cells and may be a novel platform for targeted human cancer therapy.
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